Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals?

It is no secret that in the field of biotech, small- to mid-cap companies that develop innovative therapies for difficult-to-treat diseases (such as cancer) and a variety of rare conditions are often acquired by large-cap players for billions of dollars. Last year, the biggest ever biotech deal happened when Bristol Myers Squibb (NYSE:BMY) acquired Celgene for $74 billion.